Additionally, recent approaches exploring small molecule inhibitors to disrupt the YAP1-TEAD interaction, such as Verteporfin, have demonstrated promising preclinical antitumor activity [26, 27], but have shown limited clinical efficacy due to off-target toxicity in human cancers [28]. The gene discussed is YAP1; the disease is cancer.